Dermata Enrolls First Participant in Tome Clearing Treatment Acne Trial

• Dermata Therapeutics enrolled the first participant in a clinical trial of Tome Clearing Treatment, its once-weekly acne treatment.
• The second Tome skincare product is expected to launch in the first half of 2027.
• The open-label trial targets approximately 24 participants applying treatment for 12 weeks, with an optional 12-week extension.
• Researchers will assess acne lesion counts, treatment response and post-inflammatory hyperpigmentation to support commercialization.
• The treatment combines salicylic acid, an FDA-recognized over-the-counter acne ingredient, with the company's sponge-derived Bioneedle powder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610291605ACCESSWRNAPR_____1243866) on October 29, 2026, and is solely responsible for the information contained therein.